PolyPid (PYPD) Competitors $2.99 -0.01 (-0.33%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$3.00 +0.01 (+0.50%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PYPD vs. HYPR, STIM, ECOR, PDEX, TELA, FONR, SRTS, MGRM, ICAD, and MLSSShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Hyperfine (HYPR), Neuronetics (STIM), electroCore (ECOR), Pro-Dex (PDEX), TELA Bio (TELA), FONAR (FONR), Sensus Healthcare (SRTS), Monogram Orthopaedics (MGRM), iCAD (ICAD), and Milestone Scientific (MLSS). These companies are all part of the "medical equipment" industry. PolyPid vs. Hyperfine Neuronetics electroCore Pro-Dex TELA Bio FONAR Sensus Healthcare Monogram Orthopaedics iCAD Milestone Scientific Hyperfine (NASDAQ:HYPR) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking. Which has more volatility & risk, HYPR or PYPD? Hyperfine has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Do institutionals and insiders hold more shares of HYPR or PYPD? 15.0% of Hyperfine shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 29.4% of Hyperfine shares are held by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is HYPR or PYPD more profitable? PolyPid has a net margin of 0.00% compared to Hyperfine's net margin of -309.42%. Hyperfine's return on equity of -57.54% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Hyperfine-309.42% -57.54% -50.38% PolyPid N/A -624.10%-129.28% Does the MarketBeat Community prefer HYPR or PYPD? PolyPid received 27 more outperform votes than Hyperfine when rated by MarketBeat users. Likewise, 79.49% of users gave PolyPid an outperform vote while only 44.44% of users gave Hyperfine an outperform vote. CompanyUnderperformOutperformHyperfineOutperform Votes444.44% Underperform Votes555.56% PolyPidOutperform Votes3179.49% Underperform Votes820.51% Which has higher earnings & valuation, HYPR or PYPD? PolyPid has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHyperfine$11.03M6.81-$44.24M-$0.57-1.81PolyPidN/AN/A-$29.02M-$4.97-0.60 Does the media favor HYPR or PYPD? In the previous week, Hyperfine had 1 more articles in the media than PolyPid. MarketBeat recorded 1 mentions for Hyperfine and 0 mentions for PolyPid. PolyPid's average media sentiment score of 0.00 beat Hyperfine's score of -1.00 indicating that PolyPid is being referred to more favorably in the news media. Company Overall Sentiment Hyperfine Negative PolyPid Neutral Do analysts rate HYPR or PYPD? Hyperfine presently has a consensus target price of $1.60, suggesting a potential upside of 55.34%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 279.04%. Given PolyPid's stronger consensus rating and higher probable upside, analysts plainly believe PolyPid is more favorable than Hyperfine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperfine 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00PolyPid 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryPolyPid beats Hyperfine on 12 of the 18 factors compared between the two stocks. Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.47M$4.59B$5.80B$8.95BDividend YieldN/A39.91%4.78%3.85%P/E Ratio-0.6030.6126.4518.81Price / SalesN/A49.70450.0676.66Price / CashN/A51.2344.0437.47Price / Book3.996.577.634.64Net Income-$29.02M$90.13M$3.18B$245.69M7 Day Performance1.36%-2.55%-1.85%-2.63%1 Month Performance-8.00%-2.47%0.19%-2.37%1 Year Performance-44.01%14.98%17.21%13.64% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid2.3356 of 5 stars$2.99-0.3%$11.33+279.0%-44.0%$30.47MN/A-0.6080Gap UpHYPRHyperfine2.5149 of 5 stars$1.67+3.1%$1.60-4.2%+1.0%$121.83M$11.03M-2.93190Negative NewsHigh Trading VolumeSTIMNeuronetics1.6444 of 5 stars$3.86+25.7%$4.67+20.9%+29.3%$117.15M$71.35M-3.14180High Trading VolumeECORelectroCore2.504 of 5 stars$17.04+2.7%$25.00+46.7%+151.4%$113.49M$16.03M-9.3150PDEXPro-Dex3.7438 of 5 stars$33.25-1.0%$52.00+56.4%+81.8%$108.43M$61.00M16.54140TELATELA Bio2.8073 of 5 stars$2.67flat$9.25+246.4%-61.1%$105.17M$58.45M-1.58120Positive NewsFONRFONAR2.2093 of 5 stars$16.01+2.6%N/A-35.7%$101.34M$102.88M11.44480Earnings ReportNews CoverageSRTSSensus Healthcare1.9855 of 5 stars$6.07+3.9%$14.67+141.6%+15.2%$99.49M$41.81M15.1840High Trading VolumeMGRMMonogram Orthopaedics3.7979 of 5 stars$2.82+1.1%$4.00+41.8%-24.9%$96.75M$370,000.00-6.0028News CoverageICADiCAD0.5813 of 5 stars$3.60+10.1%N/A+92.9%$95.54M$17.32M-27.69140Analyst UpgradeNews CoverageGap UpMLSSMilestone Scientific0.8096 of 5 stars$1.21-2.4%$1.25+3.3%+57.3%$94.25M$9.83M-17.2830News Coverage Related Companies and Tools Related Companies Hyperfine Alternatives Neuronetics Alternatives electroCore Alternatives Pro-Dex Alternatives TELA Bio Alternatives FONAR Alternatives Sensus Healthcare Alternatives Monogram Orthopaedics Alternatives iCAD Alternatives Milestone Scientific Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PYPD) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
